The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target
1 other identifier
interventional
300
1 country
1
Brief Summary
Radiotherapy after breast conserving therapy plays an important role in early stage breast cancer patients. It not only results in a reduction in local and regional recurrence but also decrease the death rate effectively. For adjuvant radiotherapy, supine positioning is the most common approach and has multiple advantages. Due to deformability and softness of the breast, during simulation and treatment in supine position, the breast stretches over the chest wall, especially in patients with large and pendulous glands. Thus the organs at risk (OARs) received dose increased. The radiotherapeutic toxicity are unavoidable. Some present studies show that the prone positioning of patients can improve dose homogeneity and reduce the dose distribution in OARs in patients with large and pendulous glands. Chinese women have relatively small breasts, the advantages of those have not been established. Therefore, investigators compared the parameters between supine and prone positions for whole breast irradiation after conserving surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable breast-cancer
Started Jan 2019
Typical duration for not_applicable breast-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2019
CompletedFirst Submitted
Initial submission to the registry
October 24, 2022
CompletedFirst Posted
Study publicly available on registry
November 8, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2023
CompletedJanuary 31, 2023
January 1, 2023
4.8 years
October 24, 2022
January 28, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
dose distribution of GTV
the difference of GTV (Gross tumor target) between two plans
1 year
dose distribution of CTV
the difference of CTV (clinical target volume) between two plans
1 year
dose distribution of PTV
the difference of PTV (planing target volume) between two plans
1 year
dose distribution of heart
the difference of heart dose distribution between two plans
1 year
dose distribution of ipsilateral lung
the difference of ipsilateral lung dose distribution between two plans
1 year
dose distribution of bilateral breasts
the difference of bilateral breasts dose distribution between two plans
1 year
Study Arms (1)
Breast cancer underwent scanning in the supine position
EXPERIMENTALBreast cancer patients with T1-2N0M0 stage who underwent radiation therapy after conserving surgery were enrolled. Supine scan sets were acquired during free breathing for all patients. Target volumes and organs at risk (OARs) including heart, ipsilateral lung and bilateral breast were contoured by the same radiation oncologist. The tumor bed (TB) was determined based on surgical clips. The Clinical target volume (CTV)consisted of the whole breast. The planning target volume (PTV) was CTV plus 0.5cm. The boost of PTV (PTVboost) was TB plus 0.5cm.
Interventions
the patients were placed in the prone position on a dedicated treatment board with no degree incline using an arm support (with both arms above the head). Te board contained an open aperture on one side to allow for the ipsilateral breast to hang freely away from the chest wall
Eligibility Criteria
You may qualify if:
- Breast cancer patients with T1-T2N0M0 stage who underwent radiation therapy after conserving surgery
- exhibited normal arm movement aſter surgery
- had no chronic lung diseases
- Written informed consent forms
You may not qualify if:
- Breast cancer patients with radical surgery
- could not exhibit normal arm movement after surgery
- had chronic lung diseases
- refused informed consent forms
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanxi provicial cancer hospital
Taiyuan, Shanxi, 030001, China
Related Publications (1)
Ma L, Yang Y, Ma J, Mao L, Li X, Feng L, Abulimiti M, Xiang X, Fu F, Tan Y, Zhang W, Li YX, Jin J, Li N. Correlation between AI-based CT organ features and normal lung dose in adjuvant radiotherapy following breast-conserving surgery: a multicenter prospective study. BMC Cancer. 2023 Nov 9;23(1):1085. doi: 10.1186/s12885-023-11554-2.
PMID: 37946125DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
October 24, 2022
First Posted
November 8, 2022
Study Start
January 1, 2019
Primary Completion
November 1, 2023
Study Completion
November 1, 2023
Last Updated
January 31, 2023
Record last verified: 2023-01